NATCO: PATIENTS TREATED WITH #MOLNUPIRAVIR ACHIEVED RESPONSE WITHIN 5 DAYS OF THERAPY INDICATING DURATION OF TREATMENT WITH MOLNUPIRAVIR IS SHORT, SAYS CO.: NATCO TRIAL DATA

#Sun Pharma: DCGI) reviewing clinical data of #molnupiravir for treatment of COVID in adults in India.

Co has signed a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme to manufacture & supply molnupiravir in India and to over 100 low & middle-income countries

Mankind Pharma & BDR Pharma tie up to launch anti #COVID19 pill Molulife (#Molnupiravir)